Lise-Lotte Olsson

发表

Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease*

Britt-Marie Swahn, Bart Ploeger, Tjerk Bueters, 2012, The Journal of Biological Chemistry.

Discovery of a novel warhead against beta-secretase through fragment-based lead generation.

Rutger H A Folmer, Stefan Geschwindner, S. Geschwindner, 2007, Journal of medicinal chemistry.

Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.

Britt-Marie Swahn, Johan Lindström, Stefan Berg, 2012, Journal of medicinal chemistry.

A monomeric form of iNOS can rationalise observed SAR for inhibitors of dimerisation: quantum mechanics and docking compared

Daniel J. Warner, Andrew G. Leach, Lise-Lotte Olsson, 2013 .

Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency.

Gianni Chessari, Mark Sylvester, Rutger H A Folmer, 2007, Journal of medicinal chemistry.

New aminoimidazoles as beta-secretase (BACE-1) inhibitors showing amyloid-beta (A beta ) lowering in brain.

S. Eketjäll, B. Swahn, K. Strömberg, 2012 .

New aminoimidazoles as β-secretase (BACE-1) inhibitors showing amyloid-β (Aβ) lowering in brain.

S. Eketjäll, B. Swahn, K. Kolmodin, 2012, Journal of medicinal chemistry.

Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo

S. Radford, N. Ranson, C. F. van der Walle, 2016, Scientific Reports.

An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes.

N. Blomberg, A. Breeze, S. Geschwindner, 2007, Current topics in medicinal chemistry.

Engineering Neprilysin Activity and Specificity to Create a Novel Therapeutic for Alzheimer’s Disease

A. Sandercock, S. Fowler, L. Jermutus, 2014, PloS one.